Xenetic Biosciences's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.82.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.17.
During the past 3 years, the average EBIT per Share Growth Rate was 26.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 49.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 36.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Xenetic Biosciences's EBIT per Share or its related term are showing as below:
XBIO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -226.4 Med: 47.1 Max: 64.7
Current: 26.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Xenetic Biosciences was 64.70% per year. The lowest was -226.40% per year. And the median was 47.10% per year.
XBIO's 3-Year EBIT Growth Rate is ranked better than 77.79% of 1301
companies
in the Biotechnology industry
Industry Median: 3.4
vs XBIO: 26.20
Xenetic Biosciences EBIT per Share Historical Data
The historical data trend for Xenetic Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (NAS:XBIO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Xenetic Biosciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 